...
首页> 外文期刊>Molecular and Cellular Endocrinology >Quercetin inhibited epithelial mesenchymal transition in diabetic rats, high-glucose-cultured lens, and SRA01/04 cells through transforming growth factor-beta 2/phosphoinositide 3-kinase/Akt pathway
【24h】

Quercetin inhibited epithelial mesenchymal transition in diabetic rats, high-glucose-cultured lens, and SRA01/04 cells through transforming growth factor-beta 2/phosphoinositide 3-kinase/Akt pathway

机译:槲皮素通过转化生长因子-β2/磷酸阳性3-激酶/ akt途径,抑制糖尿病大鼠,高葡萄糖培养透镜和SRA01 / 04细胞的上皮间充质转变

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Diabetic cataract (DC), an identified life-threatening secondary complication of diabetes mellitus, has proven to be a dilemma because of its multifactorial caused and progression. An increasing number of studies have shown that in addition to the maillard reaction, enhanced polyol pathway, and oxidative insults, epithelial mesenchymal transition (EMT) is related to the prevalence of DC. Quercetin, a classic flavonoid with multiple pharmacological effects has been reported to possess therapeutic efficacy in the management and treatment of this disease. However, the mechanism underlying its therapeutic efficacy in EMT of lens epithelial cells (SRA01/04) and contribution to resolving DC remains a mystery. Therefore, in this study, we investigated the effects of quercetin on EMT of SRA01/04 and high-glucose (HG) induced lens opacity accompanied by lens fibrosis induced by type-1 diabetes. Furthermore, we sought to clarify the specific mechanisms underlying these effects. At week 14 after streptozotocin (STZ) intraperitoneal administration, diabetic rats showed lens opacity accompanied with diminished antioxidant function, enhanced polyol pathway activity, and non-enzymatic glycation. Western blotting confirmed EMT in rat SRA01/04 cells with significantly increased alpha-smooth muscle actin (alpha-SMA) and decreased E-cadherin expressions. Treatment of the lens with quercetin ameliorated the oxidative stress, inhibited aldose reductase (AR) activation, reduced advanced glycation end product (AGE) production, and finally suppressed EMT in the early stages. Our in vitro results showed that high-glucose activated the transforming growth factor-beta 2/phosphoinositide 3-kinase/protein kinase B (TGF-beta 2/PI3K/Akt)signalling and EMT in SRA01/04 cells. Further, induced oxidative stress, activation of aldose reductase, and accumulation of advanced glycation end products were also involved in this process. Quercetin was potent enough to effectively ameliorate the high glucose (HG)-induced EMT of SRA01/04 cells by inhibiting the activation of TGF-beta 2/PI3K/Akt, enhancing the antioxidant capacity, inhibiting AR activity, and reducing AGE production. From the whole animal to tissues, and finally the cellular level, our results provide considerable evidence of the therapeutic potential of quercetin for DC. This might be due to its inhibition of EMT mediated through inhibition of the TGF-beta/P13K/Akt pathway. (C) 2017 Elsevier B.V. All rights reserved.
机译:糖尿病性白内障(DC),患有危及的危及生命的糖尿病的二次复杂性,已被证明是由于其多因素引起和进展而成为困境。越来越多的研究表明,除了美丽的反应,增强的多元醇途径和氧化损伤之外,上皮间充质转换(EMT)与DC的患病率有关。槲皮素,据报道,具有多种药理作用的经典黄酮类化合物在该疾病的管理和治疗中具有治疗效果。然而,镜片上皮细胞EMT(SRA01 / 04)的其治疗效果的治疗效果和对分辨率的贡献仍然是一个谜。因此,在本研究中,我们研究了槲皮素对SRA01 / 04的EMT的影响,高葡萄糖(HG)诱导的透镜不透明度伴随着由1型糖尿病诱导的镜片纤维化。此外,我们试图澄清这些效果的特定机制。在第14周,在链脲佐菌素(STZ)腹膜内给药后,糖尿病大鼠显示透镜不透明度,伴有抗氧化功能,增强的多元醇途径活性和非酶促糖糖。 Western印迹在大鼠SRA01 / 04细胞中确认EMT,具有显着增加的α-平滑肌肌动蛋白(α-SMA)和降低的E-Cadherin表达。用槲皮素治疗透镜改善氧化应激,抑制醛糖还原酶(AR)活化,降低先进的糖化末端产物(年龄)生产,最终抑制早期阶段的EMT。我们的体外结果表明,高葡萄糖在SRA01 / 04细胞中活化了转化的生长因子-β2/磷酸吡啶鎓3-激酶/蛋白激酶和EMT。此外,该方法还涉及诱导氧化应激,醛糖还原酶的活化,以及晚期糖化末端产物的积累。槲皮素通过抑制TGF-β2/ PI3K / AKT的活化,增强抗氧化能力,抑制AR活性,抑制AR活性和降低年龄生产,有效地改善高葡萄糖(Hg)诱导的SRA01 / 04细胞EMT诱导的SRA01 / 04细胞的EMT。从整个动物到组织中,最后的细胞水平,我们的结果提供了大量证据了DC槲皮素的治疗潜力。这可能是由于其抑制通过抑制TGF-β/ P13K / AKT途径介导的EMT。 (c)2017 Elsevier B.v.保留所有权利。

著录项

  • 来源
    《Molecular and Cellular Endocrinology》 |2017年第2017期|共13页
  • 作者单位

    Xuzhou Med Univ Jiangsu Key Lab New Drug Res &

    Clin Pharm Xuzhou 221004 Peoples R China;

    Xuzhou Med Univ Jiangsu Key Lab New Drug Res &

    Clin Pharm Xuzhou 221004 Peoples R China;

    Xuzhou Med Univ Jiangsu Key Lab New Drug Res &

    Clin Pharm Xuzhou 221004 Peoples R China;

    Xuzhou Med Univ Jiangsu Key Lab New Drug Res &

    Clin Pharm Xuzhou 221004 Peoples R China;

    Xuzhou Med Univ Jiangsu Key Lab New Drug Res &

    Clin Pharm Xuzhou 221004 Peoples R China;

    Xuzhou Med Univ Jiangsu Key Lab New Drug Res &

    Clin Pharm Xuzhou 221004 Peoples R China;

    China Pharmaceut Univ Jiangsu Key Lab Drug Screening Nanjing Jiangsu Peoples R China;

    Xuzhou Med Univ Jiangsu Key Lab New Drug Res &

    Clin Pharm Xuzhou 221004 Peoples R China;

    Xuzhou Med Univ Jiangsu Key Lab New Drug Res &

    Clin Pharm Xuzhou 221004 Peoples R China;

    Xuzhou Med Univ Jiangsu Key Lab New Drug Res &

    Clin Pharm Xuzhou 221004 Peoples R China;

    Xuzhou Med Univ Jiangsu Key Lab New Drug Res &

    Clin Pharm Xuzhou 221004 Peoples R China;

    Xuzhou Med Univ Jiangsu Key Lab New Drug Res &

    Clin Pharm Xuzhou 221004 Peoples R China;

    Xuzhou Med Univ Jiangsu Key Lab New Drug Res &

    Clin Pharm Xuzhou 221004 Peoples R China;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类 内分泌腺疾病及代谢病;
  • 关键词

    Quercetin; Diabetic cataract; Lens; TGF-beta 2; Akt; EMT;

    机译:槲皮素;糖尿病性白内障;镜片;TGF-β2;AKT;EMT;

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号